Edwards Evoque transcatheter tricuspid valve replacement TTVR

Evoque TTVR system linked to favorable outcomes in new real-world analysis

Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.

Shockwave Medical IVL

First-in-human data highlight IVL’s potential to treat more challenging lesions

Shockwave Medical and FastWave Medical have shared new first-in-human data on their advanced IVL offerings. Both companies are focused on addressing difficult-to-cross lesions that often cause problems for cardiologists.

Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

Cardiovascular Research Foundation is merging with Fogarty Innovation

CRF merges with Fogarty Innovation to take healthcare innovation to the next level

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 

Christian M. Spaulding, MD, PhD, at TCT 2025

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 

Medtronic Stedi Extra Support guidewire

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

'The less you drink, the better': Even minor changes in alcohol use lower hypertension risk

These new findings challenge the long-standing assumption that low levels of alcohol do not meaningfully influence a person's blood pressure.

biodegradable PFO closure device

New biodegradable PFO closure device shows early potential

Researchers tracked patients for two years, using echocardiography to confirm the devices had completely vanished. Additional studies will still be required.